Navigation Links
BioMarin to Present at the Stifel Nicolaus Healthcare Conference
Date:9/9/2010

NOVATO, Calif., Sept. 9 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Stifel Nicolaus Healthcare Conference in Boston on Friday, September 17, 2010 at 9:10 a.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... CITY, Calif. , July 24, 2014   ... specialty pharmaceutical company focused on the development and commercialization ... breakthrough pain, today confirmed the PDUFA date for Zalviso ... learned that a rumor circulated online stating the Food ... July 24, 2014 there has been no notification to ...
(Date:7/24/2014)... , and MARSEILLE, France , ... , Exclusive global license from University of Tokyo enables ... sequencing (NGS) gene panels, for blood cancers  ... test, indicate favorable prognosis for patients with bone marrow ... potential for developing companion diagnostics to guide treatment with ...
(Date:7/24/2014)... Amgen (NASDAQ: AMGN ) today announced ... Tuesday, July 29, 2014, after the close of the U.S. ... call with the investment community at 2 p.m. PT. Participating ... Bradway , chairman and chief executive officer, and other members ... the conference call will be simultaneously broadcast over the Internet ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
(Date:7/25/2014)... Unlike children, the vast majority of adults finish all of ... to a new study. This is true for ... researchers from Cornell University revealed. They noted their findings ... eating habits make better choices. "If you put it ... Wansink, director of the Cornell Food and Brand Lab, ...
(Date:7/25/2014)... genes are switched on or off plays a key ... metabolism, UT Southwestern Medical Center researchers have found., The ... obesity and diabetes, since the transcription factor involved ... influence the body,s sensitivity to insulin and leptin signaling. ... regulation of food intake and sugar disposal, and obesity ...
(Date:7/25/2014)... July 25, 2014 The American Brain ... volunteer network “ABTA CommYOUnity™” during its annual patient and ... time for the brain tumor community as we – ... and caregiver support services and funding brain tumor research ... passionate about brain tumor awareness and getting our materials ...
(Date:7/25/2014)... Progress in understanding the molecular genetics of ... promising brain tumor treatments, according to Patrick Wen, MD, ... Center for Neuro-Oncology, Dana-Farber Cancer Institute. , At the ... Conference in Chicago, July 25-26, Dr. Wen will moderate ... impacting the development of new treatments and advancing strategies ...
(Date:7/25/2014)... San Jose, CA (PRWEB) July 25, 2014 ... MaaS360 WorkPlace Partner Program . Splashtop Business and ... MaaS360 Market, and will leverage the MaaS360 WorkPlace ... corporate data. , Splashtop Business and Splashtop Enterprise offer ... using any device. High performance, ease of ...
Breaking Medicine News(10 mins):Health News:Most Adults Are Members of 'Clean Plate Club' 2Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4
... of Hodgkin lymphoma, a common form of cancer of ... white blood cells (B cells), but have lost a ... The phenotype and the characteristics of Hodgkin lymphoma cells ... (Max Delbrck Center for Molecular Medicine, MDC, Berlin-Buch and ...
... Study finds 1 in 4 terminally ill not getting ... (HealthDay News) -- Oregon,s physician-assisted suicide law may not ... with clinical depression, a new study says. , The ... in 1997, and there,s been intense debate about the ...
... understand whether they may benefit from more,intensive screening, monitoring ... deCODE genetics,(Nasdaq: DCGN ) today announced the ... of the common forms of breast cancer. For the ... with her physician,about a genetic test to better understand ...
... Nominations are now being,accepted for The 2009 ... scientists in basic or clinical research who have ... Nominations will be accepted online at http://www.pauljanssenaward.com ... independent Selection,Committee. The winner(s) will be announced in ...
... TransForce(R)2 Arch Developer ... ... global manufacturer of orthodontic products, laboratory services,and continuing education programs, announced ... their new and improved,TransForce2 Arch Developer Appliances. Two styles of the ...
... 8 The following statement was,issued today by ... bad,decisions that is a major contributing factor to ... of healthcare, reducing access and,dramatically adding to healthcare ... a significant increase according to recent polls.,Access difficulty ...
Cached Medicine News:Health News:Hodgkin lymphoma -- new characteristics discovered 2Health News:Hodgkin lymphoma -- new characteristics discovered 3Health News:Oregon's Assisted Suicide Law May Overlook Depressed Patients 2Health News:deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer 2Health News:deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer 3Health News:deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer 4Health News:deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer 5Health News:deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer 6Health News:deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer 7Health News:2009 Nominations Open for The Dr. Paul Janssen Award for Biomedical Research 2Health News:2009 Nominations Open for The Dr. Paul Janssen Award for Biomedical Research 3Health News:The Next Generation of Arch Expansion has Arrived 2Health News:HealthMadeEasy.com: Our Healthcare System Is Hemorrhaging 2Health News:HealthMadeEasy.com: Our Healthcare System Is Hemorrhaging 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: